USPTO Examiner ROBERTS LEZAH - Art Unit 1612

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18769488GUM AND TOOTH TREATMENT METHOD WITH RINSINGJuly 2024October 2024Allow310NoNo
18600658TREATMENT METHOD FOR TEETH AND GUMSMarch 2024May 2024Allow300NoNo
18431648Composition for the control of oral malodor compoundsFebruary 2024December 2024Abandon1110NoNo
18459268PEROXIDE GEL COMPOSITIONSAugust 2023July 2024Abandon1110NoNo
18234068DUAL COMPONENT ORAL COMPOSITION FOR ENHANCING REMINERALIZATION OF TEETHAugust 2023April 2025Abandon2010NoNo
18348960PEROXIDE GEL COMPOSITIONSJuly 2023July 2024Abandon1320NoNo
18337857PROCESS FOR PRODUCING A BIO-BASED SURFACTANTJune 2023June 2025Abandon2410NoNo
18322979Oral Care Compositions Comprising Hops Beta Acids And Fluoride IonsMay 2023March 2025Allow2120NoNo
18189892CALCIUM CARBONATE AND ZINC OXIDE-LOADED MICROCAPSULES AND USES THEREOFMarch 2023April 2024Abandon1211NoNo
18095800LASER ASSISTED WOUND HEALING PROTOCOL AND SYSTEMJanuary 2023March 2024Abandon1410NoNo
18149989STABILIZED STANNOUS COMPOSITIONSJanuary 2023October 2024Allow2211NoNo
18072437lntraoral Cleaning TabletNovember 2022March 2025Abandon2821NoNo
18049843PEROXIDE GEL COMPOSITIONSOctober 2022October 2023Allow1210NoNo
17949366Composition for the control of oral malodor compoundsSeptember 2022December 2024Allow2660YesNo
17752568ALIPHATIC ANIONIC COMPOUNDS AND OXIDATIVE COMPOUNDS WITH IMPROVED STABILITY AND EFFICACY FOR USE IN PHARMACEUTICAL COMPOSITIONSMay 2022March 2025Abandon3301NoNo
17752543Oral Care CompositionsMay 2022April 2023Allow1120NoYes
17735034LASER ASSISTED WOUND HEALING PROTOCOL AND SYSTEMMay 2022March 2023Allow1110NoNo
17659473PEROXIDE GEL COMPOSITIONSApril 2022September 2023Allow1720NoNo
17698618Dentifrice Composition Comprising Zinc Oxide and Zinc CitrateMarch 2022January 2024Abandon2220NoNo
17566660Oral concentrate additive masking mixuteMarch 2022April 2024Abandon2710NoNo
17591750Silver Fluoride Formulations, Methods and Devices for Caries ManagementFebruary 2022November 2023Allow2140YesNo
17648608Dental formulation comprising xylitol and propolisJanuary 2022February 2025Abandon3710NoNo
17557560Peroxide Gel CompositionsDecember 2021August 2024Abandon3221NoNo
17643818TOPIRAMATE ORAL LIQUID SUSPENSION AND USE THEREOFDecember 2021August 2023Allow2030NoNo
17643820TOPIRAMATE ORAL LIQUID SUSPENSION AND USE THEREOFDecember 2021September 2023Allow2120NoNo
17545205METHODS AND COMPOSITIONS FOR DENTAL TISSUE REPAIR AND/OR REGENERATIONDecember 2021February 2024Abandon2701NoNo
17604011SCUTELLARIA COMPOSITIONS AND METHODS FOR TASTE MODULATIONOctober 2021April 2025Abandon4220NoNo
17478635COMPOSITIONS AND METHODS OF USING SUCH COMPOSITIONS AS AN ORAL RINSESeptember 2021April 2025Abandon4321NoNo
17476189Oral Care CompositionsSeptember 2021May 2023Abandon2010NoNo
17435314ORAL CARE PRODUCTAugust 2021June 2024Allow3350YesNo
17434731STABILISED HYPOCHLOROUS SOLUTIONS AND THEIR MEDICAL COSMETIC USESAugust 2021April 2022Allow810NoNo
17422728FORMULATIONS CONTAINING ACTIVE OXYGEN COMPOUNDS AND DEVICES FOR APPLICATION THEREOFJuly 2021December 2024Allow4141YesNo
17365630Preparation for Attaching to Teeth or Surrounding Part of TeethJuly 2021June 2024Abandon3520YesNo
17309858Methods of Inhibiting Neutrophil Recruitment to the Gingival CreviceJune 2021April 2025Allow4620NoNo
17416254AQUEOUS GELS FOR DYEING OR MAKING UP THE EYEBROWSJune 2021November 2024Abandon4111NoNo
17415209ANTIMICROBIAL COMPOSITIONS COMPRISING MODIFIED CLAY AND BIPHENOLJune 2021May 2025Abandon4711NoNo
17296627COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITYMay 2021September 2024Abandon4010NoNo
17302084Stannous Salt And Sodium Tripolyphosphate Oral Care Compositions And MethodsApril 2021April 2023Abandon2310NoNo
17302095Stannous Salt And Sodium Tripolyphosphate Oral Care Compositions And MethodsApril 2021July 2023Allow2720NoNo
17229479PHARMACEUTICAL COMPOSITIONSApril 2021September 2024Abandon4101NoNo
17224347NOVEL COMPOSITIONApril 2021March 2023Allow2410NoNo
17214731Oral Care Compositions and Methods of UseMarch 2021October 2023Allow3120NoNo
17279152COMPOSITIONS AND METHODS FOR REDUCING CALCIFICATION OF HEART VALVESMarch 2021March 2025Abandon4821NoNo
17210180Methods for Manufacturing Arginine DentifriceMarch 2021October 2024Allow4340NoNo
17209293SYSTEMS, METHODS AND COMPOSITIONS FOR EFFECTIVE SANITIZING OR DISINFECTINGMarch 2021October 2023Abandon3111NoNo
17278301PROCESS FOR PRODUCING A BIO-BASED SURFACTANTMarch 2021July 2023Abandon2820NoNo
17269982ORAL COMPOSITIONSFebruary 2021October 2024Allow4411NoNo
17269428ORAL RINSE COMPOSITIONS FOR REDUCING PATHOGENS UNDERLYING AND FOR TREATING PERIODONTAL DISEASE AND ORAL MALODOR IN THE CANINEFebruary 2021September 2024Abandon4321NoNo
17175869USE OF STATINS FOR PERIODONTAL DISEASE AND BONE REGENERATIONFebruary 2021October 2022Abandon2010NoNo
17174698ORAL CARE COMPOSITIONFebruary 2021July 2024Allow4150YesNo
17169012STABILIZED STANNOUS COMPOSITIONSFebruary 2021September 2022Allow2010NoNo
17259228FUNGICIDES TO PREVENT AND CONTROL FUNGAL PATHOGENSJanuary 2021August 2024Allow4321YesYes
17256517Vegetable Paper Comprising Bast Fibres and Cosmetic Products Made ThereofDecember 2020June 2023Allow3021NoNo
17254089COMPOSITIONS AND METHODS FOR THE REDUCTION OR TREATMENT OF FIBROSISDecember 2020January 2025Abandon4911NoNo
17247099Oral Care CompositionsNovember 2020March 2023Allow2830NoNo
17057891ALCOHOL-FREE BOTANICAL ORAL CARE PRODUCTSNovember 2020March 2023Abandon2811NoNo
17057155SHARK TEETH BIOCERAMICS AND USES THEREOFNovember 2020August 2023Abandon3311NoNo
16951869TOPIRAMATE ORAL LIQUID SUSPENSION AND USE THEREOFNovember 2020May 2021Allow610YesNo
17055192TABLETS CONTAINING POLYPHOSPHATESNovember 2020May 2025Abandon5440YesYes
17054611ORAL HYGIENE COMPOSITIONS FOR PREVENTING THE FORMATION OF ORAL BIOFILMS AND PROCESS FOR PREPARING THE SAMENovember 2020February 2025Allow5141NoNo
17094489N-ACYL SARCOSINATE COMPOUNDS AND OXIDATIVE COMPOUNDS WITH IMPROVED STABILITY AND EFFICACY FOR USE IN PHARMACEUTICAL COMPOSITIONSNovember 2020June 2022Allow2010YesNo
17092304MEDICAL IMPLANTS CONTAINING SURFACE MODIFIED WITH GOLD NANOPARTICLESNovember 2020December 2024Allow4911NoNo
17090078BIOACTIVE POLYMER FOR BONE REGENERATIONNovember 2020September 2024Allow4631YesNo
17049110COSMETIC COMPOSITION OF NON-AQUEOUS THIXOTROPIC NAIL VARNISH CONTAINING A NAIL-HARDENING AGENT, USE AND IMPLEMENTATION METHODOctober 2020August 2024Abandon4641NoNo
17037766Oral Care Compositions Comprising Hops Beta Acids And Fluoride IonsSeptember 2020March 2023Allow3030YesNo
17037776Oral Care Compositions Comprising Hops Beta Acids And Metal IonsSeptember 2020February 2023Allow2930YesNo
17035863ORAL CARE COMPOSITIONS COMPRISING STANNOUS ION SOURCE, NEUTRAL AMINO ACID, AND POLYPHOSPHATESeptember 2020June 2022Allow2120YesNo
17012350DUAL MATERIAL IMPLANTSeptember 2020August 2024Allow4831NoNo
17009318PHARMACEUTICAL COMPOSITIONS COMPRISING HEPARINOIDS AND METHODS FOR PREPARING THEREOFSeptember 2020February 2023Abandon3011NoNo
17008688Oral Care Compositions Comprising Metal IonsSeptember 2020October 2023Allow3740NoNo
17009149Enhanced Toothpaste And KitsSeptember 2020September 2023Allow3631YesNo
17007859STYLING COMPOSITION FOR TEMPORARILY DEFORMING KERATINOUS FIBERS AND ITS USEAugust 2020January 2023Abandon2820NoNo
16955923DEVICE FOR MAINTAINING METAL HOMEOSTASIS, AND USES THEREOFAugust 2020April 2025Abandon5821NoNo
16928489TEETH WHITENING PRODUCT CONTAINING PIEZOELECTRIC MATERIALJuly 2020June 2024Abandon4822NoNo
16962040PHARMACEUTICAL COMPOSITION FOR SUSTAINED RELEASE DELIVERY OF BUPRENORPHINEJuly 2020June 2022Allow2320NoNo
16924647MEDICAL DEVICE SOLUTIONS FOR TREATING DENTAL DISEASE AND METHODS FOR THE TREATMENT OF DENTAL DISEASEJuly 2020February 2023Allow3121NoNo
16917731Solid Carriers for Improved Delivery of Active Ingredients in Pharmaceutical CompositionsJune 2020June 2022Abandon2410NoNo
16959186PHENYLPROPIONATE COMPOUND, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOFJune 2020April 2023Allow3421NoNo
16958739PYRAZOLAMIDE COMPOUND HAVING INSECTICIDAL ACTIVITY AND USE THEREOFJune 2020March 2023Abandon3321YesNo
16959127METHOD TO PREPARE A FILLER WITH A HYALURONIC ACID BASEJune 2020July 2022Allow2510NoNo
16958881USE OF CHLOROGENIC ACID IN PREPARATION OF DRUG FOR TREATING CHORDOMAJune 2020September 2022Allow2720YesNo
16958140INDOMETHACIN MENTHYL ESTER-BASED PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ANTI-INFLAMMATORY AGENTSJune 2020August 2022Abandon2611NoNo
16957577COMPOSITION FOR IMPROVING INTESTINAL BARRIER FUNCTIONJune 2020October 2022Abandon2721NoNo
16911369METHODS TO TREAT INFLAMMATORY AND SMOOTH MUSCLE CELL PROLIFERATION DISORDERSJune 2020March 2025Abandon5651NoNo
16957425Personal Care CompositionsJune 2020March 2024Allow4540YesNo
16898466Kits Comprising Unit-Dose Oral Care CompositionsJune 2020November 2024Allow5351NoNo
16946132TOPIRAMATE ORAL LIQUID SUSPENSION AND USE THEREOFJune 2020July 2021Allow1310YesNo
16877500ORAL HYGIENE DROPLETSMay 2020March 2023Abandon3420NoNo
16763068THICKENER SYSTEMS FOR ORAL CARE COMPOSITIONS AND A METHOD FOR PREPARING THE SAMEMay 2020October 2023Allow4141YesNo
16859288Low Water Stannous Fluoride Plus Zinc Citrate Dentifrice with Improved Stability, Rheology, and EfficacyApril 2020November 2021Allow1910NoNo
16833092Resurrection Of Antibiotics That MRSA Resists By Silver-Doped Bioactive Glass-Ceramic ParticlesMarch 2020October 2023Allow4231YesNo
16832603ORAL COMPOSITIONMarch 2020October 2020Allow710NoNo
16828326Oral Care CompositionsMarch 2020July 2023Allow3941NoNo
16796440STABLE ANHYDROUS TOOTHPASTE CONCENTRATE FORMULATION AND METHOD OF MAKING SAMEFebruary 2020February 2022Abandon2411NoNo
16784563Peroxide Gel CompositionFebruary 2020January 2021Abandon1110NoNo
16784582Peroxide Gel CompositionFebruary 2020November 2021Allow2220NoNo
16784086COSMETIC AND TOPICAL COMPOSITIONS COMPRISING CANNABIGEROLFebruary 2020June 2022Abandon2820NoNo
16781388REDUCTION OF TOOTH STAINING DERIVED FROM CATIONIC ANTIBACTERIALSFebruary 2020December 2021Allow2230YesNo
16777936Oral Care Compositions and Methods of UseJanuary 2020August 2021Allow1910NoNo
16737132Oral Care Compositions and Methods of UseJanuary 2020May 2023Abandon4060NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROBERTS, LEZAH.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
65
Examiner Affirmed
59
(90.8%)
Examiner Reversed
6
(9.2%)
Reversal Percentile
21.5%
Lower than average

What This Means

With a 9.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
170
Allowed After Appeal Filing
24
(14.1%)
Not Allowed After Appeal Filing
146
(85.9%)
Filing Benefit Percentile
14.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 14.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ROBERTS, LEZAH - Prosecution Strategy Guide

Executive Summary

Examiner ROBERTS, LEZAH works in Art Unit 1612 and has examined 769 patent applications in our dataset. With an allowance rate of 46.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner ROBERTS, LEZAH's allowance rate of 46.3% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ROBERTS, LEZAH receive 3.05 office actions before reaching final disposition. This places the examiner in the 96% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ROBERTS, LEZAH is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +37.3% benefit to allowance rate for applications examined by ROBERTS, LEZAH. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.8% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 21.1% of cases where such amendments are filed. This entry rate is in the 19% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 47.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 39% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 53.9% of appeals filed. This is in the 20% percentile among all examiners. Of these withdrawals, 55.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 49.7% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.9% of allowed cases (in the 82% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.3% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.